Anyone with any clue about corporate finance will tell you it is utterly ridiculous to render a pre-commercial biotech unable to raise capital. The appearance of it alone would cause grave concern on the part of both new investors and partners, not to mention a new CEO, etc.
News 
Market Data 
Discover 
AI
